Glenwood Gum of Absorption Systems to Present at Ocular Diseases & Drug Discovery Conference in San Diego on March 20th
SAN DIEGO, March 4, 2014 /PRNewswire/ — Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that Dr. Glenwood Gum, Associate Director, Preclinical Operations, will present a talk at the 6(th) Ocular Diseases & Drug Discovery Conference on March 20(th) in San Diego. The title of his presentation is “Developing Predictive Preclinical Models for Novel Anterior Segment Drug Delivery.” The conference, organized by Global Technology Community (GTC), will run March 20(th) and 21(st) at the Hyatt Regency Mission Bay.
The scientific program for the conference is impressive, with distinguished speakers representing industry (drug and medical device developers), contract research organizations, academic research centers, and the National Eye Institute of the National Institutes of Health.
“It’s an honor to be on the program with so many scientists whom I’ve gotten to know over the years and are working on some really cutting-edge therapies,” said Dr. Gum. “I look forward to exchanging ideas, learning about the latest developments in the field, and representing Absorption Systems.” His talk will include the development and application of novel preclinical models of diseases of the front (anterior segment) of the eye, as well as case studies in which new drug delivery systems have been evaluated.
Since joining Absorption Systems in 2011, Dr. Gum has spearheaded the establishment of a center of excellence in ocular drug delivery at Absorption Systems’ AAALAC-accredited facility in San Diego. Prior to that, he became well-known by developing or co-developing many of the preclinical models of glaucoma, macular degeneration (AMD), retinoblastoma, uveitis, and diabetes that are used all over the world for drug testing. Over the course of his long career, he has authored or co-authored more than 100 publications and book chapters. “And,” he adds, “I still get a kick out of going into the lab every day and working with a customer to figure out the best way to study their product using the considerable tools at our disposal. Who knows, maybe tomorrow we’ll work on a cure for AMD.”
Serving more than 250 different customers annually throughout the globe, and with over 110 employees based in facilities in Exton, PA, San Diego, CA, and Panama City, Panama, Absorption Systems is a global leader in contract research for the life sciences industry. With a clear vision of the future and an unwavering commitment to innovation, the company is poised for even stronger growth going forward.
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems’ commitment to innovation and is soon to be an industry standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, in San Diego, CA, and in Panama, and serves customers throughout the world. For information on the company’s comprehensive contract services and applied research programs, please visit absorption.com.
SOURCE Absorption Systems